Clinical data
AHFS/ International Drug Names
Routes of
ATC code L01DB04 (WHO)
Legal status
Legal status
  • ℞ (Prescription only)
CAS Number 57576-44-0 N
PubChem (CID) 42474
ChemSpider 1931 YesY
UNII 74KXF8I502 YesY
KEGG D02756 YesY
Chemical and physical data
Formula C42H53NO15
Molar mass 811.86 g/mol
3D model (Jmol) Interactive image
Melting point 151 to 153 °C (304 to 307 °F) (decomposes)
 NYesY (what is this?)  (verify)

Aclarubicin (INN) or aclacinomycin A[1] is an anthracycline drug[2] that is used in the treatment of cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. It can induce histone eviction from chromatin upon intercalation.[3][4]


  1. CID 451415 from PubChem
  2. Jensen PB, Jensen PS, Demant EJ, et al. (October 1991). "Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II". Cancer Res. 51 (19): 5093–9. PMID 1655244.
  3. Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J (2013). "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". Nature Communications. 4: 1908. doi:10.1038/ncomms2921. PMID 23715267.
  4. Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J (2015). "Chemical profiling of the genome with anti-cancer drugs defines target specificities". Nature Chemical Biology. 11 (7): 472. doi:10.1038/nchembio.1811. PMID 25961671.

This article is issued from Wikipedia - version of the 7/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.